Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): The RAISE Connection Program Duration of Untreated Psychosis (DUP)
2 other identifiers
interventional
65
1 country
2
Brief Summary
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years. The DUP sub-study will collect pathways to care information that will be used to inform the development and pilot testing of strategies that aim to reduce DUP among individuals experiencing a first episode of psychosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable schizophrenia
Started Oct 2010
Longer than P75 for not_applicable schizophrenia
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2010
CompletedFirst Submitted
Initial submission to the registry
October 4, 2010
CompletedFirst Posted
Study publicly available on registry
October 7, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2016
CompletedNovember 3, 2016
November 1, 2016
4.3 years
October 4, 2010
November 2, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
This measures occupational functioning, social functioning and symptom severity.
Measured at baseline
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
Measured at Month 6
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
Measured at Month 12
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
Measured at Month 18
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
Measured at Month 24
Pathways to Care Qualitative Interview
This assessment gathers information on help-seeking events and participant recommendations.
Measured at baseline
Secondary Outcomes (15)
The Clinical Global Impression (CGI) - Severity scale
Measured at baseline
Calgary Depression Scale
Measured at baseline
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
Measured at baseline
The Clinical Global Impression (CGI) - Severity scale
Measured at Month 6
The Clinical Global Impression (CGI) - Severity scale
Measured at Month 12
- +10 more secondary outcomes
Study Arms (1)
Team-based treatment
EXPERIMENTALInterventions
Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
Eligibility Criteria
You may qualify if:
- Age range: 15-35 years old (16-35 years old in New York)
- Diagnosis of schizophrenia, schizoaffective and schizophreniform disorder, delusional disorder, or psychosis not otherwise specified (NOS)
- Duration of psychotic symptoms \> 1 week and \< 2 years
- Ability to provide informed consent
- Ability to speak and understand English
- Anticipated availability to participate in the intervention for at least 1 year
- RAISE-DUP: participants must have been enrolled in the RAISE study
You may not qualify if:
- Medical conditions which impair function independent of psychosis
- Other diagnoses associated with psychosis:
- Substance-induced psychotic disorder
- Psychotic affective disorder (major depressive or manic episode with psychotic features)
- Psychotic disorder due to a general medication condition
- Mental retardation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Research Foundation for Mental Hygiene, Inc.lead
- National Institute of Mental Health (NIMH)collaborator
- University of Marylandcollaborator
- New York State Office of Mental Health (OMH)collaborator
- Maryland Department of Health and Mental Hygienecollaborator
Study Sites (2)
University of Maryland Medical Center, Carruthers Clinic
Baltimore, Maryland, 21230, United States
Washington Heights Community Service Clinic
New York, New York, 10032, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lisa Dixon, MD
Columbia University
- PRINCIPAL INVESTIGATOR
Melanie Bennett, PhD
University of Maryland
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director Center for Practice Innovations
Study Record Dates
First Submitted
October 4, 2010
First Posted
October 7, 2010
Study Start
October 1, 2010
Primary Completion
January 1, 2015
Study Completion
August 1, 2016
Last Updated
November 3, 2016
Record last verified: 2016-11